(SeaPRwire) –
Nasdaq just pulled the plug on Charming Medical. The delisting is now official. The company failed to request a hearing by the November 5, 2026 deadline. Trading halts at the open on November 9, 2026. This is not a standard compliance miss. It smells like a total failure of basic market hygiene.
Look at the SEC files. From November 12 to November 25, 2025, trading was suspended. The reason? Unknown persons recommended buying or holding shares via social media. They asked for transaction screenshots. It was a classic pump-and-dump play. Nasdaq halted trading on November 26, 2025. That halt never ended. The stock never recovered.
The delisting relies on Listing Rule IM-5101-4. This rule grants Nasdaq broad discretion to delist companies involved in potential misconduct. The key trigger here is the SEC’s temporary suspension for manipulation. The company claims its operations remain normal. But the market signal is clear. Investors have lost trust.
Where does this leave the TCM-inspired wellness sector? It is a graveyard for speculative micro-caps. Without a verifiable price discovery mechanism, these stocks become tools for manipulators. For anyone holding MCTA, check the OTC availability. Liquidity will be thin. Volatility will be high. Protect your capital. The era of easy tech listing for niche lifestyle plays is over. Nasdaq is cleaning house.